| Literature DB >> 30136572 |
Rebecca J Holley1, Shaun R Wood1, Brian W Bigger1.
Abstract
Neurological lysosomal storage diseases are rare, inherited conditions resulting mainly from lysosomal enzyme deficiencies. Current treatments, such as enzyme replacement therapy and hematopoietic stem cell transplantation, fail to effectively treat neurological disease due to insufficient brain delivery of the missing enzyme. Ex vivo gene therapy approaches to overexpress the missing enzyme in hematopoietic stem cells prior to transplant are an emerging technology that has the potential to offer a viable therapy for patients with these debilitating diseases.Entities:
Keywords: enzyme replacement therapy; gene therapy; hematopoietic stem cells; lysosomal storage diseases; mucopolysaccharidoses
Mesh:
Year: 2018 PMID: 30136572 DOI: 10.1021/acschemneuro.8b00408
Source DB: PubMed Journal: ACS Chem Neurosci ISSN: 1948-7193 Impact factor: 4.418